PEGylated Drugs Market in Europe and North America worth over $10.5 billion by 2024: Global Market Insights, Inc.
April 17, 2018 04:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, April 17, 2018 (GLOBE NEWSWIRE) -- North America and Europe PEGylated Drugs Market is expected to surpass USD 10.5 billion by 2024; according to a new research report by...
New Pathogen-Detection Technology Identifies Infectious Diseases
May 26, 2016 13:51 ET
|
ARUP Laboratories
SALT LAKE CITY, May 26, 2016 (GLOBE NEWSWIRE) -- ARUP Laboratories Medical Director Robert Schlaberg, MD, Dr Med, MPH, will be the Principal Investigator for a project to help decrease the high...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...
OnCore Biopharma Closes Series R Financing
September 05, 2014 07:00 ET
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
June 07, 2012 07:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
The new patent filed 6 June aims to strengthen the Company's general protection of its...
Immunitor Completes Phase IIb imm01 Trial Enrollment and Plans Further Trials of V5
November 14, 2010 23:21 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 14, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that its potential acquisition, Immunitor USA Inc., has announced the completion of...
Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
November 01, 2010 09:42 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...
SafeShot Technologies Files Patents on New Low-Dose Version of Its Revolutionary Safety Injection Technology Called "Epiphany Ultra"
September 14, 2010 09:45 ET
|
SafeShot Technologies
MISSION VIEJO, CA--(Marketwire - September 14, 2010) - SafeShot Technologies, LLC, a leader in safety syringe innovation, today announced the successful development and patent filings on a new...
IMSCO Issues License for Detection and Removal of Viral and Bacterial Contaminants in Blood and Blood Products
August 26, 1999 12:31 ET
|
IMSCO Technologies
NEW YORK, Aug. 26, 1999 (PRIMEZONE) -- IMSCO has issued a license for its unique proprietary electrostatic separation technology to BIOELECTRIC SEPARATION, INC., (BSI) a New York Corporation and...